Use of disodium pamidronate bisphosphonate in patients with bone metastases of lung cancer
Disodium pamidronate (Aredia®), a drug of the bisphosphonate group, was administered to 20 patients with pains in the bones due to secondary deposits of lung cancer. The aim of the study was to investigate the analgesic effect of pamidronate to osteolytic metastases of lung cancer in the bone. In 16...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade
2002-01-01
|
| Series: | Vojnosanitetski Pregled |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0042-8450/2002/0042-84500201033R.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850181321199976448 |
|---|---|
| author | Ranković Boško Mrđa Vladimir |
| author_facet | Ranković Boško Mrđa Vladimir |
| author_sort | Ranković Boško |
| collection | DOAJ |
| description | Disodium pamidronate (Aredia®), a drug of the bisphosphonate group, was administered to 20 patients with pains in the bones due to secondary deposits of lung cancer. The aim of the study was to investigate the analgesic effect of pamidronate to osteolytic metastases of lung cancer in the bone. In 16 (80%) patients non-small-cell lung cancer was diagnosed, and in 4 (20%) patients small-cell-lung cancer was confirmed. Intensive disseminated pains in the bones were present in all the patients. Metastases in the skeleton were confirmed by radiography and scintigraphy of the bones. Initial values of calcium in the plasma were determined in those patients. In 11 (55%) patients, initial values of calcium in the serum were normal, and in 9 (45%) patients, they were elevated. Patients with normal calcium values received 30 mg of pamidronate in 250 ml of normal saline, and patients with hypercalcaemia received 45-60 mg in 500 ml of normal saline. Analgesic effect of pamidronate was present in 12 (60%) patients, and the completely painless state was achieved in 4 out of 12 patients. Evaluation of the pain was done by questionnaire, using a simple, descriptive scale. In all 9 (100%) patients with hypercalcaemia, values of calcium in plasma were normalized. Pamidronate exerted favorable analgesic effect in the case of metastases of lung cancer in the bones in more than 50% patients. Satisfactory results were also achieved in the patients non-responsive to palliative therapy by irradiation This enables the use of opiates in lower doses. |
| format | Article |
| id | doaj-art-4c31c73eb666438aaeef25136dfd9ccd |
| institution | OA Journals |
| issn | 0042-8450 |
| language | English |
| publishDate | 2002-01-01 |
| publisher | Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade |
| record_format | Article |
| series | Vojnosanitetski Pregled |
| spelling | doaj-art-4c31c73eb666438aaeef25136dfd9ccd2025-08-20T02:17:56ZengMinistry of Defence of the Republic of Serbia, University of Defence, BelgradeVojnosanitetski Pregled0042-84502002-01-01591333610.2298/VSP0201033RUse of disodium pamidronate bisphosphonate in patients with bone metastases of lung cancerRanković BoškoMrđa VladimirDisodium pamidronate (Aredia®), a drug of the bisphosphonate group, was administered to 20 patients with pains in the bones due to secondary deposits of lung cancer. The aim of the study was to investigate the analgesic effect of pamidronate to osteolytic metastases of lung cancer in the bone. In 16 (80%) patients non-small-cell lung cancer was diagnosed, and in 4 (20%) patients small-cell-lung cancer was confirmed. Intensive disseminated pains in the bones were present in all the patients. Metastases in the skeleton were confirmed by radiography and scintigraphy of the bones. Initial values of calcium in the plasma were determined in those patients. In 11 (55%) patients, initial values of calcium in the serum were normal, and in 9 (45%) patients, they were elevated. Patients with normal calcium values received 30 mg of pamidronate in 250 ml of normal saline, and patients with hypercalcaemia received 45-60 mg in 500 ml of normal saline. Analgesic effect of pamidronate was present in 12 (60%) patients, and the completely painless state was achieved in 4 out of 12 patients. Evaluation of the pain was done by questionnaire, using a simple, descriptive scale. In all 9 (100%) patients with hypercalcaemia, values of calcium in plasma were normalized. Pamidronate exerted favorable analgesic effect in the case of metastases of lung cancer in the bones in more than 50% patients. Satisfactory results were also achieved in the patients non-responsive to palliative therapy by irradiation This enables the use of opiates in lower doses.http://www.doiserbia.nb.rs/img/doi/0042-8450/2002/0042-84500201033R.pdflung neoplasmsneoplasm metastasisbone neoplasmsdiphosphonatesanalgesia |
| spellingShingle | Ranković Boško Mrđa Vladimir Use of disodium pamidronate bisphosphonate in patients with bone metastases of lung cancer Vojnosanitetski Pregled lung neoplasms neoplasm metastasis bone neoplasms diphosphonates analgesia |
| title | Use of disodium pamidronate bisphosphonate in patients with bone metastases of lung cancer |
| title_full | Use of disodium pamidronate bisphosphonate in patients with bone metastases of lung cancer |
| title_fullStr | Use of disodium pamidronate bisphosphonate in patients with bone metastases of lung cancer |
| title_full_unstemmed | Use of disodium pamidronate bisphosphonate in patients with bone metastases of lung cancer |
| title_short | Use of disodium pamidronate bisphosphonate in patients with bone metastases of lung cancer |
| title_sort | use of disodium pamidronate bisphosphonate in patients with bone metastases of lung cancer |
| topic | lung neoplasms neoplasm metastasis bone neoplasms diphosphonates analgesia |
| url | http://www.doiserbia.nb.rs/img/doi/0042-8450/2002/0042-84500201033R.pdf |
| work_keys_str_mv | AT rankovicbosko useofdisodiumpamidronatebisphosphonateinpatientswithbonemetastasesoflungcancer AT mrđavladimir useofdisodiumpamidronatebisphosphonateinpatientswithbonemetastasesoflungcancer |